Literature DB >> 96841

Chrysotherapy in psoriatic arthritis. Efficacy and toxicity compared to rheumatoid arthritis.

B B Dorwart, E P Gall, H R Schumacher, R E Krauser.   

Abstract

Chrysotherapy was given to 14 patients with refractory psoriatic polyarthritis and to a comparable group of 42 patients with rheumatoid arthritis. The psoriatic patients had a higher rate of remission on gold and less severe toxicity than the rheumatoid arthritis patients. Psoriatic skin lesions were not affected by chrysotherapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 96841     DOI: 10.1002/art.1780210504

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  13 in total

Review 1.  Spondylarthropathies: options for combination therapy.

Authors:  A M van Tubergen; R B Landewé; S van der Linden
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Gold or penicillamine?

Authors:  R C Offer
Journal:  Can Fam Physician       Date:  1981-02       Impact factor: 3.275

3.  Long term experience with oral gold in psoriatic arthritis.

Authors:  P Barbieri; M L Ciompi; C Bini; G Pasero
Journal:  Clin Rheumatol       Date:  1986-06       Impact factor: 2.980

4.  Oral gold for rheumatoid arthritis.

Authors:  V Wright
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-06

Review 5.  Evolution of the psoriatic arthritis concept and its relationship to the spondarthritides.

Authors:  J M Moll
Journal:  Clin Rheumatol       Date:  1982-09       Impact factor: 2.980

Review 6.  Antirheumatic drugs: clinical pharmacology and therapeutic use.

Authors:  G L Craig; W W Buchanan
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

7.  Seronegative spondylarthritis.

Authors: 
Journal:  West J Med       Date:  1981-02

Review 8.  The optimum management of arthropathies.

Authors:  C S Wolfe; G R Hughes
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

9.  Treatment of psoriatic arthritis with auranofin and gold sodium thiomalate.

Authors:  W Brückle; T Dexel; K Grasedyck; M Schattenkirchner
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

10.  Clinical response to auranofin in patients with psoriatic arthritis.

Authors:  C Salvarani; F Zizzi; P Macchioni; W Mantovani; F Rossi; R Baricchi; A Bellelli; N Capozzoli; L Frizziero; I Portioli
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.